Eris Lifesciences Limited (NSE:ERIS) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Last week, you might have seen that Eris Lifesciences Limited (NSE:ERIS) released its second-quarter result to the market. The early response was not positive, with shares down 2.7% to ₹1,550 in the past week. Revenues of ₹7.9b were in line with forecasts, although statutory earnings per share (EPS) came in below expectations at ₹8.81, missing estimates by 2.1%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the consensus forecast from Eris Lifesciences' ten analysts is for revenues of ₹33.0b in 2026. This reflects a decent 11% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to leap 26% to ₹38.32. Before this earnings report, the analysts had been forecasting revenues of ₹33.4b and earnings per share (EPS) of ₹39.10 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

View our latest analysis for Eris Lifesciences

The analysts reconfirmed their price target of ₹1,811, showing that the business is executing well and in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Eris Lifesciences at ₹1,980 per share, while the most bearish prices it at ₹1,530. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Eris Lifesciences is an easy business to forecast or the the analysts are all using similar assumptions.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Eris Lifesciences'historical trends, as the 23% annualised revenue growth to the end of 2026 is roughly in line with the 21% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 11% annually. So although Eris Lifesciences is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at ₹1,811, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Eris Lifesciences going out to 2028, and you can see them free on our platform here.

It is also worth noting that we have found 2 warning signs for Eris Lifesciences that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.